Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Receivables (2016 - 2026)

Pharma-Bio Serv's Receivables history spans 17 years, with the latest figure at $2.7 million for Q1 2026.

  • For Q1 2026, Receivables fell 49.91% year-over-year to $2.7 million; the TTM value through Jan 2026 reached $2.7 million, down 49.91%, while the annual FY2025 figure was $2.4 million, 5.98% down from the prior year.
  • Receivables reached $2.7 million in Q1 2026 per PBSV's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $5.5 million in Q2 2022 to a low of $2.0 million in Q3 2025.
  • Average Receivables over 5 years is $4.2 million, with a median of $4.8 million recorded in 2022.
  • Peak YoY movement for Receivables: skyrocketed 771.07% in 2022, then plummeted 61.97% in 2025.
  • A 5-year view of Receivables shows it stood at $5.0 million in 2022, then fell by 20.91% to $3.9 million in 2023, then plummeted by 36.29% to $2.5 million in 2024, then fell by 5.98% to $2.4 million in 2025, then increased by 12.45% to $2.7 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Receivables are $2.7 million (Q1 2026), $2.4 million (Q4 2025), and $2.0 million (Q3 2025).